Skip to main content
. 2018 Oct 31;132(26):2763–2774. doi: 10.1182/blood-2017-10-812941

Figure 2.

Figure 2.

Nrf2−/−donor T cells induced less GVHD mortality and morbidity. (A-C) Lethally irradiated BALB/c recipients that received WT B6 TCD BM alone or with 0.5 × 106 B6 WT or Nrf2−/− T cells were monitored daily for Kaplan-Meier survival analysis (A) and weekly for GVHD clinical scores (B) and weight loss (C). Data represent the mean ± standard error of the mean from 3 independent experiments (BM, n = 14; BM + WT T, n = 29; BM + Nrf2−/− T, n = 30). Lethally irradiated LP recipients that received WT B6 TCD BM alone or with 2 × 106 B6 WT or Nrf2−/− T cells were monitored daily for survival (D) and weekly for GVHD clinical scores (E) and weight loss (F). Data represent the mean ± standard error of the mean from 3 independent experiments (n = 6 in BM group, n = 12 each in BM WT T and Nrf2−/− T groups). ***P < .005.